Drug intelligence / Profile preview

Xiaoke Kang Granules

Development stage: Unknown
Lead developer: Hebei Wanbang Fu Lin Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Xiaoke Kang Granules is a traditional Chinese medicine (TCM) formulation developed and manufactured by Hebei Wanbang Fu Lin Pharmaceutical. It is specifically indicated for the treatment of 'Xiaoke' (thirst-quenching) syndrome, which in traditional Chinese medicine corresponds to symptoms associated with diabetes mellitus, such as excessive thirst, frequent urination, and fatigue. As a multi-herb formulation, its mechanism of action is based on TCM principles of nourishing yin and clearing heat to alleviate the symptoms of internal heat and fluid deficiency. It is administered orally in granule form and is currently approved and marketed in China.

Brand names: Xiaoke Kang Granules消渴康颗粒
Other names: Xiaoke Kang

Beyond the preview

Go deeper on Xiaoke Kang Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiaoke Kang Granules.

Explore the full profile